Back

How do we identify patients with HFpEF?

30 August 2025 (13:00 - 13:12)
Organised by: Logo
Congress Presentation Part of: Therapy in action: optimising heart failure care with SGLT2 inhibitors for outpatients Chronic Heart Failure Open Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Clara Ines Saldarriaga

Cardio Clinical VID, Medellin (Colombia)

5 More presentations in this session

Presentation thumbnail
Welcome and introduction
Professor B. Bozkurt (Houston, US)
Slides
Presentation thumbnail
Why still talk about implementation of SGLT2 inhibitors?
Professor B. Bozkurt (Houston, US)
Presentation thumbnail
What are the barriers we need to break?
Professor P. Campbell (Newry, GB)
Presentation thumbnail
What are the wider benefits of SGLT2 inhibitors for cardio-renal-metabolic conditions?
Professor N. Marx (Aachen, DE)
Presentation thumbnail
Close
Professor B. Bozkurt (Houston, US)

Access the full session

Session thumbnail
Therapy in action: optimising heart failure care with SGLT2 inhibitors for outpatients
Video

The Event

Event poster

ESC Congress 2025

30 August 2025 13:00 CET
You may be interested in
thumbnail
Congress Session
HFpEF: modern approaches to diagnosis and management
17 May 2025
thumbnail
Congress Presentation
Differences in clinical characteristics and outcomes in real-world HFpEF patients according to clinical definitions
27 August 2021
thumbnail
Congress Presentation
Real-world identification of patients with HFpEF in a tertiary hospital in the Netherlands: the IDENTIFY-HFpEF study
10 May 2026
thumbnail
Webinar
GLP-1 RAs and HFpEF: which HFpEF patients should now be receiving GLP-1 RAs?
15 December 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources